Business context and reporting period
The supplied filing is China Jo-Jo Drugstores, Inc.’s Form 20-F, not a filing identified as Ridgetech Inc. It is an annual report for the fiscal year ended March 31, 2024; it does not provide standalone 2023 Q4 results. China Jo-Jo is a Cayman Islands holding company whose China pharmacy, online pharmacy, wholesale and clinic operations are conducted through subsidiaries and contractual VIE arrangements. It reported 127 pharmacies, all in Hangzhou.
Key financial metrics
| Metric | FY2024 | FY2023 |
|---|---|---|
| Revenue | $154.5 million | $148.8 million |
| Gross profit / margin | $31.1 million / 20.1% | $34.3 million / 23.0% |
| Operating loss / margin | $3.5 million / (2.3%) | $20.9 million / (14.1%) |
| Net loss | $4.2 million | $21.1 million |
| Net cash used in operating activities | $3.2 million | $3.3 million |
| Net cash used in investing activities | $2.0 million | $0.3 million |
| Net cash provided by financing activities | $8.0 million | $2.4 million |
Revenue rose 3.8%. Retail pharmacy revenue fell 9.2% to $75.7 million; online revenue fell 1.6% to $31.9 million; wholesale revenue rose 42.1% to $47.0 million. Farming revenue was zero. Retail, online and wholesale gross margins were 29.9%, 11.3% and 10.4%, respectively.
At March 31, 2024, cash and cash equivalents were $20.1 million and restricted cash was $12.7 million. Current assets of $69.7 million were below current liabilities of $74.4 million, resulting in a $4.7 million working-capital deficit. Total liabilities were $80.8 million and shareholders’ equity was $14.3 million. Current obligations included $31.7 million of notes payable, a $0.3 million short-term loan and $4.9 million of current operating lease liabilities; long-term lease liabilities were $6.4 million. Notes payable are generally short-term bank acceptance bills, with restricted cash pledged as collateral.
Material changes versus the prior comparable period
- Gross margin contracted 2.9 percentage points, principally as retail margins weakened amid price competition and changes to reimbursed-drug pricing.
- Operating loss narrowed substantially, mainly as general and administrative expense declined to $7.3 million from $15.7 million. The prior year included $10.4 million of stock-based compensation and a $7.6 million increase in bad-debt allowance; FY2024 recorded a credit-loss reversal.
- Net loss improved by $16.9 million. FY2024 nevertheless included a $1.6 million investment loss, primarily related to impairment of an investment.
- Operating cash outflow remained significant. Financing cash flow increased, including proceeds from notes payable and a private placement.
- The company opened 14 stores and reported 127 locations at year-end, up from 114. Same-store retail sales declined approximately 10.9%.
Outlook, commentary and risks
Management provided no quantified revenue or earnings guidance. It cited local consumer frugality, a saturated and highly competitive Hangzhou pharmacy market, reduced retail margins and online price competition. Management expects wholesale platforms may offer growth opportunities and is exploring acquisitions; it also said new insurance-reimbursement certificates could support sales at newer stores. It stated that available resources are expected to support operations for at least 12 months, while acknowledging reliance on financing and repayment of short-term obligations.
After year-end, the company disclosed registered direct offerings of 900,000, 1,610,000 and 1,980,000 shares at $1.70 per share, for aggregate gross proceeds of $7.633 million. Together with the September 2023 private placement, it cited total gross proceeds of $10.223 million. A further 420,715 restricted shares were granted to the CEO on April 1, 2024. These transactions create dilution. Nasdaq bid-price compliance was regained in March 2024 after a 1-for-20 reverse split; continued compliance is not assured.
Key risks include the VIE structure’s dependence on contractual arrangements rather than ownership, uncertainty in PRC regulation and the ability to move funds out of China, foreign-exchange exposure, supplier and landlord deposits, credit and reimbursement-claim collectability, and competition. The company reported ineffective disclosure controls and internal control over financial reporting as of March 31, 2024, citing weaknesses in U.S. GAAP expertise, China-to-U.S. GAAP reconciliations, and revenue and receivable collectability controls. Management described remediation efforts. The independent auditor issued an unqualified opinion on the financial statements, but did not audit or opine on internal-control effectiveness.
The filing reports no material pending legal proceedings and no cash dividends paid or expected in the foreseeable future. It identifies no material cybersecurity incidents. Principal unusual items include the prior-year stock compensation, the FY2024 investment impairment, and post-year-end equity issuances and CEO share award.
Most important facts for investors to verify
- Confirm the issuer identity: the filing names China Jo-Jo Drugstores, Inc. (Nasdaq: CJJD), not Ridgetech Inc.
- Reconcile the cash-flow disclosure: the primary cash-flow statement reports $3.155 million used in operations, while a subsequent liquidity discussion says approximately $2.9 million.
- Assess near-term liquidity, including the $4.7 million working-capital deficit, $31.7 million of notes payable, collateral restrictions, maturities and available bank facilities.
- Review the effectiveness and progress of remediation of the disclosed material weaknesses in financial reporting controls, and the quality of receivable and government-insurance reimbursement estimates.
- Quantify fully diluted share count and ownership effects from the post-year-end offerings, warrants and CEO share award; compare with the filing’s differing share counts at March 31 and July 30, 2024.
- Evaluate the enforceability and practical risks of the VIE contracts, PRC regulatory and remittance restrictions, and the concentration of operations in China.